AstraZeneca’s Breakthrough Hypertension Drug Nears FDA Approval
AstraZeneca’s baxdrostat cut blood pressure by nearly 10 mmHg in phase 3 trials, moving closer to FDA approval as a potential breakthrough for resistant hypertension.
AstraZeneca is advancing its late-stage hypertension drug, baxdrostat, toward FDA approval after reporting strong phase 3 results showing clinically meaningful reductions in blood pressure. In a pivotal trial of 796 patients with uncontrolled hypertension, baxdrostat, an aldosterone synthase inhibitor, demonstrated average placebo-adjusted drops in systolic blood pressure (SBP) of 8.7 mmHg with the 1 mg dose and 9.8 mmHg with the 2 mg dose after 12 weeks.
The treatment nearly tripled the chances of patients achieving target SBP levels below 130 mmHg compared to placebo, while also delivering greater reductions in diastolic blood pressure. Results were consistent across both uncontrolled and treatment-resistant hypertension populations, underscoring the potential of baxdrostat to become a breakthrough therapy for patients who do not respond to existing antihypertensive drugs.
Mechanism and Market Position
The late-stage data were presented at the European Society of Cardiology Congress in Spain and add momentum to AstraZeneca’s cardiovascular pipeline strategy. Baxdrostat works by selectively inhibiting CYP11B2, the gene responsible for aldosterone synthesis, while avoiding interference with cortisol production, a limitation seen with older drugs. The candidate was originally licensed by CinCor from Roche before AstraZeneca acquired CinCor for $1.3 billion in January 2023. At the time, the deal appeared risky as baxdrostat had recently missed a key phase 2 endpoint, but AstraZeneca’s long-standing interest allowed it to secure favorable acquisition terms.
According to Sharon Barr, AstraZeneca’s senior vice president of biopharmaceuticals R&D, the company is preparing regulatory filings with health authorities and sees baxdrostat as an opportunity to address “one of the most difficult problems in cardiovascular care—hypertension that remains uncontrolled despite multiple treatments.” Beyond hypertension, AstraZeneca is conducting additional phase 3 studies to evaluate the drug’s 24-hour ambulatory blood pressure effects and to explore its potential across conditions where aldosterone plays a role, including chronic kidney disease and heart failure prevention.
The hypertension drug landscape remains highly competitive. While Roche and Alnylam are advancing their RNAi candidate zilebesiran into phase 3 despite a phase 2 setback, AstraZeneca’s baxdrostat appears well-positioned as a differentiated, selective therapy targeting aldosterone. If approved, it could emerge as a key addition to the global antihypertensive market, offering new hope to millions of patients with resistant high blood pressure.
